Optic Nerve Disorders Drug Development Pipeline Review, 2018 – ResearchAndMarkets.com

DUBLIN –(BUSINESS WIRE)

The “Optic Nerve Disorders Drug Development Pipeline Review, 2018” report has been added to ResearchAndMarkets.com’s offering.

This report provides an overview of the pipeline landscape for disorders of the optic nerve, the bundle of nerve fibers that transmits visual information from the eye to the brain. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for optic neuropathy, glaucoma, Leber’s hereditary optic neuropathy (LHON) and optic neuritis, and features dormant and discontinued products.

  • Optic Neuropathy – There are 10 products in development for this indication.
  • Glaucoma – There are 13 products in development for this indication.
  • LHON – There are 16 products in development for this indication.
  • Optic Neuritis – There are 12 products in development for this indication.

Molecular targets acted on by products in development for optic nerve disorders include kinases, growth factors and cannabinoid receptors. Companies operating in this pipeline space include NicOx SA Regeneron Pharmaceuticals and Amgen

Key Topics Covered

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Optic Nerve Disorders Report Coverage

2.2 Optic Neuropathy – Overview

2.3 Glaucoma – Overview

2.4 Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) – Overview

2.5 Optic Neuritis – Overview

3 Therapeutics Development

3.1 Optic Neuropathy

3.2 Glaucoma

3.3 Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)

3.4 Optic Neuritis

4 Therapeutics Assessment

4.1 Optic Neuropathy

4.2 Glaucoma

4.3 Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)

4.4 Optic Neuritis

5 Companies Involved in Therapeutics Development

5.1 Optic Neuropathy

5.2 Glaucoma

5.3 Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)

5.4 Optic Neuritis

6 Dormant Projects

6.1 Optic Neuropathy

6.2 Glaucoma

6.3 Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)

6.4 Optic Neuritis

7 Discontinued Products

7.1 Optic Neuropathy

7.2 Glaucoma

7.3 Optic Neuritis

8 Product Development Milestones

8.1 Optic Neuropathy

8.2 Glaucoma

8.3 Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)

8.4 Optic Neuritis

Companies Featured

  • AC Immune SA
  • Aerie Pharmaceuticals Inc
  • Alkeus Pharmaceuticals Inc
  • Allergan Plc
  • Altacor Ltd
  • Coma
  • Commence Bio Inc
  • D. Western Therapeutics Institute Inc
  • Disarm Therapeutics Inc
  • Dompe Farmaceutici SpA
  • Fortress Biotech Inc
  • GenSight Biologics SA
  • Gene Signal International SA
  • InMed Pharmaceuticals Inc
  • Inspyr Therapeutics Inc
  • Isarna Therapeutics GmbH
  • Ixchel Pharma LLC
  • Khondrion BV
  • Lipocure Ltd
  • Meta-IQ ApS
  • MimeTech Srl
  • Mitobridge Inc
  • Mitochon Pharmaceuticals Inc
  • Mitotech SA
  • Neuritis
  • Pivot Pharmaceuticals Inc
  • Profarma
  • Q BioMed Inc
  • ReNetX Bio
  • Sylentis SAU
  • Taejoon Pharm Co Ltd
  • Teijin Pharma Ltd
  • TikoMed AB
  • Unity Biotechnology Inc
  • and many more…

For more information about this report visit https://www.researchandmarkets.com/research/x67cvr/optic_nerve?w=4

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Drug Discovery, Central Nervous System Drugs

Copyright Business Wire 2018

Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and have questions or removal requests please contact [email protected]